Tagged with R&D

USA Kendalle O’Connell, President and CEO of MassBio, shares how Massachusetts has built one of the world’s most dynamic life sciences hubs through a mix of bold public investment, targeted programmes, and a “big tent” approach to collaboration. From guiding companies into the right communities with the BioReady programme to fostering…

Puerto Rico Long celebrated for its world-class pharmaceutical and medical device manufacturing, Puerto Rico is now leveraging this strong foundation to nurture a new era of research and development. Rather than shifting away from production, the island is integrating R&D directly into its manufacturing operations — from pilot plants and small-scale prototyping…

France Serge Picaud, the Executive Director of the Paris Vision Institute outlines a bold vision to transform ophthalmology through cutting-edge research and innovation. From pioneering the first successful optogenetic vision restoration to advancing therapies for AMD, myopia, and diabetic retinopathy, the institute blends academic excellence with commercial impact supported by 15…

Denmark As clinical trials increasingly drift toward Asia and the US, can Denmark offer a blueprint for revitalising Europe’s competitive edge?   As Europe’s leader in clinical trials per capita, Denmark combines a deep domestic commitment to cutting-edge research with strong international confidence as a destination for investment. In 2023, the…

Denmark Neuroscience is once again at the forefront of medical innovation, and Lundbeck is seizing the moment to redefine its future. In this wide-ranging conversation, President & CEO Charl van Zyl outlines how the company is evolving from a heritage-rich organisation into a focused, performance-driven innovator with a maturing pipeline and…

Global As neuroscience reclaims a place at the top table of pharmaceutical innovation, Bristol Myers Squibb (BMS) is quietly reshaping its presence in the field. Spearheaded by its Neuroscience Thematic Research Center, the company is pursuing a dual mandate: to slow the progression of diseases like Alzheimer’s while also addressing their…

Denmark Ian Laquian’s journey from Big Pharma strategy leadership to entrepreneurial venture creation exemplifies the innovative thinking required to address intractable neurological challenges. Having spearheaded CNS therapeutic area strategy at Takeda Pharmaceuticals, Laquian has pioneered a ground-breaking approach that leverages metabolic pathways to treat neurodegenerative diseases. Through the establishment of Kariya…

Denmark As Denmark positions itself as a rising force in global life sciences, the BioInnovation Institute (BII) stands at the centre of this momentum, bridging world-class academic research with entrepreneurial ambition. In this conversation, CEO Jens Nielsen shares how BII is scaling its proven model, shaping Denmark’s innovation environment, and drawing…

Switzerland Switzerland is a crucial country for MSD’s global network, employing over 1000 people in local, regional, and global functions across four sites in Lucerne and a newly opened site in Zurich specialising in R&D, data management, and commercialisation. With 25 ongoing clinical trials per year, Switzerland is an important country…

Switzerland As global science faces mounting complexity, the Paul Scherrer Institute (PSI) stands out as a model of long-term vision, technical excellence, and interdisciplinary ambition. Director Christian Rüegg discusses how PSI is advancing the frontiers of oncology, neuroscience, energy, and AI – developing radiopharmaceuticals and imaging entire neural networks, to enabling…

Denmark Already one of Europe’s top countries for clinical trials per capita, Denmark has further strengthened its position in recent years. The number of active trials in the country rose from 410 in 2022 to 450 in 2023, backed by increasing citizen participation and a healthcare ecosystem built on trusted health…

USA Having terminated dozens of HIV-related research grants, the Trump administration’s assault on the field continues. In a major blow to the decades-long search for a vaccine, the US federal government has pulled the plug on the HIV vaccine programme run by the US National Institute of Health (NIH) –the world’s…